AR039409A1 - Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso. - Google Patents
Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso.Info
- Publication number
- AR039409A1 AR039409A1 ARP030101280A ARP030101280A AR039409A1 AR 039409 A1 AR039409 A1 AR 039409A1 AR P030101280 A ARP030101280 A AR P030101280A AR P030101280 A ARP030101280 A AR P030101280A AR 039409 A1 AR039409 A1 AR 039409A1
- Authority
- AR
- Argentina
- Prior art keywords
- dry powder
- inhalation
- pharmaceutical composition
- derivatized
- treatment
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 5
- 238000004519 manufacturing process Methods 0.000 title 1
- 239000000843 powder Substances 0.000 abstract 7
- 239000013543 active substance Substances 0.000 abstract 3
- 150000001720 carbohydrates Chemical class 0.000 abstract 3
- 235000014633 carbohydrates Nutrition 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000002664 inhalation therapy Methods 0.000 abstract 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 206010014561 Emphysema Diseases 0.000 abstract 1
- WOTQVEKSRLZRSX-JRFIZLOQSA-N [(2r,3r,4s,5r,6r)-4,5,6-triacetyloxy-3-[(2s,3r,4s,5s,6r)-3,4,5-triacetyloxy-6-(acetyloxymethyl)oxan-2-yl]oxyoxan-2-yl]methyl acetate Chemical group CC(=O)OC[C@H]1O[C@H](OC(C)=O)[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H]1O[C@H]1[C@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](OC(C)=O)[C@@H](COC(C)=O)O1 WOTQVEKSRLZRSX-JRFIZLOQSA-N 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 206010006451 bronchitis Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 210000002345 respiratory system Anatomy 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 206010039083 rhinitis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Pulmonology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Composiciones farmacéuticas en polvo y a su uso en el tratamiento de trastornos respiratorios por inhalación. También inhaladores de polvo seco que comprenden las mismas. Más particularmente, se describen composiciones farmacéuticas de polvo seco de estabilidad mejorada. Los inhaladores de polvo seco (IPS) son dispositivos bien conocidos para administrar agentes farmacéuticamente activos al tracto respiratorio. En consecuencia, son particularmente adecuados cuando se utilizan para la administración de agentes activos en el tratamiento de enfermedades tales como asma, bronquitis, enfermedad obstructiva crónica (EPOC), enfisema, rinitis, etc. Reivindicación 1: el uso de carbohidratos derivatizados particulados en composiciones farmacéuticas en polvo seco para terapia por inhalación para mejorar el comportamiento de estabilidad. Reivindicación 3: una composición farmacéutica en polvo seco para terapia por inhalación, que comprende un agente farmacéuticamente activo, un excipiente y un carbohidrato derivatizado en forma pariculada. Reivindicación 7: Una composición farmacéutica en polvo seco según la reivindicación 3, en la que el carbohidrato derivatizado es octaacetato de alfa-D-celobiosa.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0208608.0A GB0208608D0 (en) | 2002-04-13 | 2002-04-13 | Composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039409A1 true AR039409A1 (es) | 2005-02-16 |
Family
ID=9934855
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030101280A AR039409A1 (es) | 2002-04-13 | 2003-04-11 | Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20050244340A1 (es) |
| EP (1) | EP1494644A1 (es) |
| JP (1) | JP2005530733A (es) |
| KR (1) | KR20040099436A (es) |
| CN (1) | CN1658839A (es) |
| AR (1) | AR039409A1 (es) |
| AU (1) | AU2003217073A1 (es) |
| BR (1) | BR0309114A (es) |
| CA (1) | CA2481467A1 (es) |
| GB (1) | GB0208608D0 (es) |
| IL (1) | IL164420A0 (es) |
| IS (1) | IS7500A (es) |
| MX (1) | MXPA04010080A (es) |
| NO (1) | NO20044497L (es) |
| PL (1) | PL373294A1 (es) |
| RU (1) | RU2004130439A (es) |
| TW (1) | TW200404008A (es) |
| WO (1) | WO2003088943A1 (es) |
| ZA (1) | ZA200408245B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024396A2 (en) | 2001-09-17 | 2003-03-27 | Glaxo Group Limited | Dry powder medicament formulations |
| SE526509C2 (sv) * | 2003-06-19 | 2005-09-27 | Microdrug Ag | Kombinerade doser av formoterol och budesonid separerade på en gemensam dosbädd |
| WO2005004845A1 (en) * | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Pharmaceutical formulations comprising magnesium stearate |
| WO2005004846A1 (en) * | 2003-07-11 | 2005-01-20 | Glaxo Group Limited | Pharmaceutical formulations |
| AR049384A1 (es) | 2004-05-24 | 2006-07-26 | Glaxo Group Ltd | Derivados de purina |
| WO2006066907A1 (en) * | 2004-12-21 | 2006-06-29 | Glaxo Group Limited | Pharmaceutical formulations |
| US9365905B2 (en) * | 2005-02-10 | 2016-06-14 | Dmv-Fonterra Excipients Technology Gmbh | Processes for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| EP2046787B1 (en) | 2006-08-01 | 2011-04-06 | Glaxo Group Limited | Pyrazolo[3,4-b]pyridine compounds, and their use as pde4 inhibitors |
| GB0921075D0 (en) * | 2009-12-01 | 2010-01-13 | Glaxo Group Ltd | Novel combination of the therapeutic agents |
| MX2015015132A (es) * | 2013-04-29 | 2016-02-18 | Sanofi Sa | Composiciones farmaceuticas inhalables y los dispositivos inhaladores que las contienen. |
| US20170252333A1 (en) * | 2014-08-01 | 2017-09-07 | Luxena Pharmaceuticals, Inc. | Palonosetron formulations and uses thereof |
| PT109030B (pt) * | 2015-12-15 | 2019-09-25 | Hovione Farmaciência, S.A. | Preparação de partículas inaláveis de zafirlucaste |
| CN110237373B (zh) * | 2018-03-08 | 2023-06-02 | 润生药业有限公司 | 一种生产用于联合用药的药物载体的装置及方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR8007911A (pt) * | 1979-12-06 | 1981-06-16 | Glaxo Group Ltd | Inalador aperfeicoado |
| SE448277B (sv) * | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| BE905189A (fr) * | 1985-07-30 | 1987-01-29 | Glaxo Group Ltd | Dispositif pour administrer des medicaments a des patients. |
| GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| JPH04220268A (ja) * | 1990-12-19 | 1992-08-11 | Olympus Optical Co Ltd | バルーンカテーテル |
| US6517860B1 (en) * | 1996-12-31 | 2003-02-11 | Quadrant Holdings Cambridge, Ltd. | Methods and compositions for improved bioavailability of bioactive agents for mucosal delivery |
| DK0994887T3 (da) * | 1997-07-03 | 2003-03-17 | Elan Drug Delivery Ltd | Modificerede glycosider, præparater omfattet deraf og fremgangsmåder til anvendelse deraf |
| US6352722B1 (en) * | 1997-12-23 | 2002-03-05 | Quadrant Holdings Cambridge Limited | Derivatized carbohydrates, compositions comprised thereof and methods of use thereof |
| NZ511527A (en) * | 1998-11-13 | 2002-10-25 | Jago Res A | Dry powder for inhalation |
| GB9916316D0 (en) * | 1999-07-12 | 1999-09-15 | Quadrant Holdings Cambridge | Dry powder compositions |
| GB0015981D0 (en) * | 2000-06-29 | 2000-08-23 | Glaxo Group Ltd | Novel process for preparing crystalline particles |
| GB0020616D0 (en) * | 2000-08-21 | 2000-10-11 | Quadrant Holdings Cambridge | Particulates |
| AU3664102A (en) * | 2000-12-01 | 2002-06-11 | Battelle Memorial Institute | Method for stabilizing biomolecules in liquid formulations |
| GB0103630D0 (en) * | 2001-02-14 | 2001-03-28 | Glaxo Group Ltd | Chemical compounds |
-
2002
- 2002-04-13 GB GBGB0208608.0A patent/GB0208608D0/en not_active Ceased
-
2003
- 2003-04-10 CN CN038137194A patent/CN1658839A/zh active Pending
- 2003-04-10 WO PCT/GB2003/001542 patent/WO2003088943A1/en not_active Ceased
- 2003-04-10 PL PL03373294A patent/PL373294A1/xx not_active Application Discontinuation
- 2003-04-10 CA CA002481467A patent/CA2481467A1/en not_active Abandoned
- 2003-04-10 AU AU2003217073A patent/AU2003217073A1/en not_active Abandoned
- 2003-04-10 US US10/511,042 patent/US20050244340A1/en not_active Abandoned
- 2003-04-10 BR BR0309114-7A patent/BR0309114A/pt not_active IP Right Cessation
- 2003-04-10 JP JP2003585695A patent/JP2005530733A/ja active Pending
- 2003-04-10 MX MXPA04010080A patent/MXPA04010080A/es unknown
- 2003-04-10 RU RU2004130439/15A patent/RU2004130439A/ru not_active Application Discontinuation
- 2003-04-10 EP EP03712461A patent/EP1494644A1/en not_active Withdrawn
- 2003-04-10 KR KR10-2004-7016302A patent/KR20040099436A/ko not_active Withdrawn
- 2003-04-11 TW TW092108394A patent/TW200404008A/zh unknown
- 2003-04-11 AR ARP030101280A patent/AR039409A1/es not_active Application Discontinuation
-
2004
- 2004-10-05 IL IL16442004A patent/IL164420A0/xx unknown
- 2004-10-11 IS IS7500A patent/IS7500A/is unknown
- 2004-10-12 ZA ZA200408245A patent/ZA200408245B/xx unknown
- 2004-10-21 NO NO20044497A patent/NO20044497L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1658839A (zh) | 2005-08-24 |
| EP1494644A1 (en) | 2005-01-12 |
| KR20040099436A (ko) | 2004-11-26 |
| MXPA04010080A (es) | 2004-12-13 |
| US20050244340A1 (en) | 2005-11-03 |
| RU2004130439A (ru) | 2005-06-10 |
| NO20044497L (no) | 2004-11-15 |
| PL373294A1 (en) | 2005-08-22 |
| TW200404008A (en) | 2004-03-16 |
| BR0309114A (pt) | 2005-02-01 |
| AU2003217073A1 (en) | 2003-11-03 |
| JP2005530733A (ja) | 2005-10-13 |
| ZA200408245B (en) | 2007-03-28 |
| CA2481467A1 (en) | 2003-10-30 |
| IS7500A (is) | 2004-10-11 |
| GB0208608D0 (en) | 2002-05-22 |
| IL164420A0 (en) | 2005-12-18 |
| WO2003088943A1 (en) | 2003-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1326595E (pt) | Composicao farmaceutica compreendendo resveratrol para o tratamento de disturbios respiratorios inflamatorios | |
| AR039409A1 (es) | Composicion farmaceutica en polvo seco para inhalacion, fabricacion y uso. | |
| BR0308274A (pt) | Formulação de formoterol superfino | |
| NO20061254L (no) | Farmasoytiske blandinger | |
| RU2018138195A (ru) | Соединения 3,5-диамино-6-хлор-n-(n-(4- фенилбутил)карбамимидоил)пиразин-2-карбоксамида | |
| UY26959A1 (es) | Nuevos polvos para inhalación que contienen tiotropio | |
| US20110189106A1 (en) | Intranasal compositions, dosage forms and methods of treatment | |
| NO20024708D0 (no) | Behandling av respiratoriske sykdommer | |
| NO20075042L (no) | Farmasoytisk sammensetning innbefattende en omega-karboksyarylsubstituert difenylurea for behandling av cancer | |
| AR015820A1 (es) | Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas | |
| CO5550426A2 (es) | Novedoso metodo terapeutico | |
| HRP20220929T3 (hr) | Sastav za inhalaciju koji sadrži aklidinij za liječenje astme | |
| AR039408A1 (es) | Composicion farmaceutica en polvo seco para terapia por inhalacion y uso para fabricacion de un medicamento | |
| BR0306663A (pt) | Formulação de salmeterol superfino | |
| KR20250143851A (ko) | 신규한 다기능성 올리고펩타이드 | |
| PE20020793A1 (es) | Agente preventivo y/o terapeutico de enfermedades inflamatorias del tracto respiratorio | |
| UY30935A1 (es) | Combinacion:-antagonista del receptor de quimioquina 1 (ccr1) -agonista del receptor de glucocorticoides- opcionalmente agonista b(beta)2, -composicion farmacéutica conteniéndola -aplicaciones. | |
| BRPI0409380A (pt) | composições farmacêuticas | |
| EA200600886A1 (ru) | Способ получения солей тиотропия, соли тиотропия, а также содержащие их лекарственные композиции | |
| RU2007138263A (ru) | Противовоспалительные соединения | |
| UY28096A1 (es) | Nueva formulación pulveurlenta que contiene tiotropio destinada a la inhalación | |
| CN105496992A (zh) | 氨溴索沙丁胺醇脂质固体分散体 | |
| BR0308984A (pt) | Formulações em pó adequadas para inalação | |
| WO2007046113A3 (en) | Novel pharmaceutical composition comprising alkaloid and process thereof | |
| WO2005011615A3 (en) | Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |